68 trials changed in the last 30 days: 3 stopped, 19 with notable changes, 46 with minor changes only.
Withdrawn before enrolling
Also in this update: Primary and study completion pushed from Dec 7, 2028 to Jan 22, 2029
Novartis PharmaceuticalsPhase 3 NCT07625306 Registry history of NCT07625306 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Trial sites reduced: 103 → 74 locations; Study completion date changed from estimate of Sep 28, 2028 to Oct 1, 2026
Novartis PharmaceuticalsPhase 2 NCT05268289 Registry history of NCT05268289 on ClinicalTrials.gov (opens the registry)
Trial status changed: Recruiting → Withdrawn
Also in this update: Trial sites reduced: 25 → 0 locations
Novartis PharmaceuticalsPhase 2 NCT07039422 Registry history of NCT07039422 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Oct 30, 2026 to Jun 25, 2027
Also in this update: Study completion pushed from Oct 31, 2026 to Jun 25, 2027
Novartis PharmaceuticalsPhase 1 NCT03891953 Registry history of NCT03891953 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Nov 30, 2026 to May 31, 2027
Novartis PharmaceuticalsNot specified NCT07677267 Registry history of NCT07677267 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Nov 30, 2026 to May 31, 2027
Novartis PharmaceuticalsNot specified NCT07677254 Registry history of NCT07677254 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 30, 2026 to Jun 30, 2028
Novartis PharmaceuticalsNot specified NCT07710716 Registry history of NCT07710716 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Feb 22, 2036 to Apr 18, 2039
Also in this update: Enrollment reduced: 1400 → 1105 participants
Novartis PharmaceuticalsPhase 3 NCT02445222 Registry history of NCT02445222 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 8, 2030 to Apr 3, 2034
Also in this update: Trial sites expanded: 143 → 162 locations; Study completion pushed from Apr 5, 2032 to Oct 2, 2034
Novartis PharmaceuticalsPhase 3 NCT06133972 Registry history of NCT06133972 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 2, 2028 to Jan 29, 2029
Also in this update: Enrollment increased: 104 → 140 participants; Study completion pushed from Sep 30, 2030 to Jun 18, 2031
Novartis PharmaceuticalsPhase 2 NCT06997588 Registry history of NCT06997588 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified
Novartis PharmaceuticalsPhase 1/2 NCT07190300 Registry history of NCT07190300 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date pushed from Oct 14, 2026 to Oct 15, 2026; Study completion moved earlier from Jul 17, 2028 to Jan 18, 2028
Novartis PharmaceuticalsPhase 1 NCT07855276 Registry history of NCT07855276 on ClinicalTrials.gov (opens the registry)
Enrollment reopened
Also in this update: Enrollment increased: 448 → 540 participants; Trial sites expanded: 155 → 161 locations
Novartis PharmaceuticalsPhase 3 NCT04557462 Registry history of NCT04557462 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Nov 9, 2026 to Sep 21, 2026; Primary and study completion moved earlier from Jul 17, 2028 to Jun 2, 2028; and 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07816328 Registry history of NCT07816328 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 3 locations
Novartis PharmaceuticalsPhase 2 NCT07748624 Registry history of NCT07748624 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Primary and study completion pushed from Sep 16, 2027 to Oct 19, 2027; Start date changed from estimate of Nov 9, 2026 to Sep 18, 2026; and 3 more changes in the last 30 days
Novartis PharmaceuticalsPhase 2 NCT07830719 Registry history of NCT07830719 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Novartis PharmaceuticalsPhase 1 NCT07783503 Registry history of NCT07783503 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 21, 2026 to Sep 22, 2026
Novartis PharmaceuticalsNot specified NCT07598448 Registry history of NCT07598448 on ClinicalTrials.gov (opens the registry)
Start date pushed from Aug 25, 2026 to Nov 1, 2026
Also in this update: Trial status changed: Recruiting → Not Yet Recruiting; and 4 more changes in the last 30 days
Novartis PharmaceuticalsNot specified NCT07737756 Registry history of NCT07737756 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 6, 2026
Novartis PharmaceuticalsPhase 4 NCT04230148 Registry history of NCT04230148 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 11, 2026 to Sep 11, 2026
Novartis PharmaceuticalsPhase 2 NCT03827798 Registry history of NCT03827798 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 655 → 646 locations
Novartis PharmaceuticalsPhase 3 NCT07517263 Registry history of NCT07517263 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 97 → 89 locations
Novartis PharmaceuticalsPhase 3 NCT06875973 Registry history of NCT06875973 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 132 → 121 locations
Novartis PharmaceuticalsPhase 3 NCT06868212 Registry history of NCT06868212 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 128 → 106 locations
Novartis PharmaceuticalsPhase 2 NCT06470048 Registry history of NCT06470048 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 246 participants (planned 340)
Novartis PharmaceuticalsPhase 3 NCT06813911 Registry history of NCT06813911 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 130 → 120 locations
Novartis PharmaceuticalsPhase 3 NCT06744920 Registry history of NCT06744920 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 25 participants (planned 40)
Novartis PharmaceuticalsPhase 1/2 NCT07468071 Registry history of NCT07468071 on ClinicalTrials.gov (opens the registry)
Trial completed
Novartis PharmaceuticalsPhase 1/2 NCT05798117 Registry history of NCT05798117 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 670 participants (planned 600)
Novartis PharmaceuticalsNot specified NCT05217810 Registry history of NCT05217810 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 31, 2026 to Jan 5, 2027
Novartis PharmaceuticalsNot specified NCT07770074 Registry history of NCT07770074 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Feb 25, 2027 to Jun 30, 2027
Novartis PharmaceuticalsNot specified NCT07635316 Registry history of NCT07635316 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Feb 13, 2032 to Mar 15, 2032
Also in this update: Study completion pushed from Sep 4, 2035 to Oct 4, 2035
Novartis PharmaceuticalsPhase 2 NCT06991556 Registry history of NCT06991556 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 24, 2026 to Dec 8, 2026
Novartis PharmaceuticalsPhase 1 NCT07465653 Registry history of NCT07465653 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 16, 2026 to Mar 30, 2027
Novartis PharmaceuticalsNot specified NCT07454850 Registry history of NCT07454850 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 134 → 137 locations
And 8 more changes in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07357727 Registry history of NCT07357727 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 40 → 43 locations
Novartis PharmaceuticalsPhase 3 NCT07456891 Registry history of NCT07456891 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 12 → 18 locations
And 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07498335 Registry history of NCT07498335 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 206 → 236 participants
Novartis PharmaceuticalsPhase 2 NCT04589650 Registry history of NCT04589650 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 100 → 106 locations
And 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT06855277 Registry history of NCT06855277 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 42 → 64 locations
Novartis PharmaceuticalsPhase 3 NCT07498426 Registry history of NCT07498426 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 4 → 7 locations
Also in this update: Start date changed from estimate of Oct 6, 2026 to Oct 7, 2026; and 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07811869 Registry history of NCT07811869 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 14 → 18 locations
And 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07768371 Registry history of NCT07768371 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 34 → 44 locations
And 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07665437 Registry history of NCT07665437 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 7 → 12 locations
Novartis PharmaceuticalsPhase 2 NCT07681271 Registry history of NCT07681271 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 26 → 33 locations
And 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07621809 Registry history of NCT07621809 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 256 → 296 locations
Novartis PharmaceuticalsPhase 3 NCT07225504 Registry history of NCT07225504 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 13 → 17 locations
And 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07700056 Registry history of NCT07700056 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 30 → 34 locations
Novartis PharmaceuticalsPhase 2 NCT07354074 Registry history of NCT07354074 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 120 → 152 participants
Also in this update: Trial sites expanded: 3 → 6 locations
Novartis PharmaceuticalsPhase 1 NCT07626281 Registry history of NCT07626281 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 55 → 59 locations
Novartis PharmaceuticalsPhase 2 NCT07441642 Registry history of NCT07441642 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 76 → 83 locations
Novartis PharmaceuticalsPhase 2 NCT07431177 Registry history of NCT07431177 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 18 → 21 locations
Also in this update: Start date changed from estimate of Sep 10, 2026 to Sep 29, 2026; and 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 2 NCT07775924 Registry history of NCT07775924 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 4 → 7 locations
Novartis PharmaceuticalsNot specified NCT07683065 Registry history of NCT07683065 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 10 → 13 locations
Novartis PharmaceuticalsPhase 1/2 NCT06546670 Registry history of NCT06546670 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 81 → 93 locations
Novartis PharmaceuticalsPhase 2/3 NCT06780670 Registry history of NCT06780670 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 82 → 117 locations
Novartis PharmaceuticalsPhase 3 NCT07326709 Registry history of NCT07326709 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 9 → 20 locations
Novartis PharmaceuticalsPhase 2 NCT07737743 Registry history of NCT07737743 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 5 → 9 locations
Novartis PharmaceuticalsPhase 1 NCT07570979 Registry history of NCT07570979 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 65 → 69 locations
Novartis PharmaceuticalsNot specified NCT07549516 Registry history of NCT07549516 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 89 → 82 locations
Novartis PharmaceuticalsNot specified NCT06551519 Registry history of NCT06551519 on ClinicalTrials.gov (opens the registry)
Primary and study completion moved earlier from Aug 20, 2027 to Jun 22, 2027
Novartis PharmaceuticalsPhase 2 NCT04980833 Registry history of NCT04980833 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Dec 31, 2026 to Oct 28, 2026
Novartis PharmaceuticalsPhase 2 NCT05445843 Registry history of NCT05445843 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Nov 1, 2031 to Oct 1, 2031
Novartis PharmaceuticalsPhase 1/2 NCT04925479 Registry history of NCT04925479 on ClinicalTrials.gov (opens the registry)
Start date changed from estimate of Sep 22, 2026 to Sep 8, 2026
Novartis PharmaceuticalsPhase 1 NCT07801508 Registry history of NCT07801508 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 15, 2026 to Sep 30, 2026
Novartis PharmaceuticalsNot specified NCT07465666 Registry history of NCT07465666 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-19 | NCT07881783 A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With… | Not Yet Recruiting | |
| 2026-10-09 | NCT07868328 A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary… | Phase 2 | Not Yet Recruiting |
| 2026-10-02 | NCT07855276 A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to… | Phase 1 | Recruiting |
| 2026-09-30 | NCT07850752 A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With… | Phase 3 | Not Yet Recruiting |
| 2026-09-28 | NCT07843758 An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant… | Completed | |
| 2026-09-28 | NCT07844070 A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During… | Active, Not Recruiting | |
| 2026-09-24 | NCT07839858 A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment… | Completed | |
| 2026-09-21 | NCT07830719 Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With… | Phase 2 | Recruiting |
| Phase 1 | 43 | |
| Phase 1/2 | 26 | |
| Phase 2 | 68 | |
| Phase 2/3 | 2 | |
| Phase 3 | 90 | |
| Phase 4 | 25 |
Breast Cancer (33) · Prostate Cancer (32) · Leukemia (27) · Multiple Sclerosis (27) · Lung Cancer (23) · Heart Disease (22) · Non-Small Cell Lung Cancer (NSCLC) (18) · Chronic Myeloid Leukemia (CML) (15) · Hidradenitis Suppurativa (15) · Colorectal Cancer (9)